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Background. Accurate, early diagnosis and the initiation of appropriate treatment is
central to reducing the clinical burden of coronary artery disease (CAD); however, real-world
evidence characterizing healthcare resource utilization (HCRU) associated with testing for
CAD is lacking.
Methods and Results. Using a non-interventional, retrospective, secondary database analysis, patients aged ‡18 years who underwent outpatient non-invasive cardiac diagnostic testing
were identified. The primary objective was to gain an understanding of pre- and post-assessment care pathways and the associated interventions for patients who underwent non-invasive
testing for CAD in either an outpatient or emergency department setting. Overall, chest pain
was the primary reason for the index visit (54.8%), followed by shortness of breath (23.7%),
myocardial infarction (MI), coronary artery disease (CAD) or congestive heart failure (CHF)
(3.8%), and other (46.8%); 3.0% of patients had no apparent reason for testing in the last 45
days. Single-photon emission computed tomography (SPECT) was the dominant diagnostic
testing modality (40.3%). During the 90-day follow-up, 7.3% (n = 22,083) of patients were
diagnosed with CAD; among these patients, 19.4% had repeat diagnostic testing, 26.0% of
patients had a revascularization procedure, and 65.6% underwent cardiac catheterization.
These rates varied by testing modality.
Conclusions. In this study of a large real-world data sample, variability in the use of noninvasive tests and HCRU were evident. These results may assist efforts to optimize system-wide
care/diagnostic pathways and value-based treatment decisions for patients. (J Nucl Cardiol
2021)
Key Words: CAD < diseases/processes Æ SPECT < modalities Æ ETT < tests Æ Diagnostic and
prognostic application < outcomes
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INTRODUCTION
In the United States (US), cardiovascular disease is
responsible for one in 3 deaths annually with coronary
artery disease (CAD) resulting in one in 7 all-cause
deaths.1,2 Consequently, evaluations for suspected CAD
account for a substantial percentage of ambulatory
health care visits as early diagnosis and treatment are
critical to minimizing the clinical burden associated with
CAD.3 Accordingly, various non-invasive tests are
widely available for diagnosing CAD, including coronary artery calcium (CAC) for identifying early
coronary atherosclerosis; exercise treadmill testing
(ETT), stress echocardiography (SE), single-photon
emission computed tomography (SPECT), positron
emission tomography (PET), and stress magnetic resonance imaging (MRI) for evaluating functional aspects
of ischemia; and coronary computed tomography
angiography (CTA) and invasive angiography to identify anatomic evidence of ischemia.4 Locally available
resources and expertise are the primary factors that
influence which non-invasive testing modality is used,
and indications for testing are adopted using published
appropriate use criteria and clinical practice guidelines.5
One of the biggest challenges that healthcare
systems face is ensuring efficient delivery of care.6–9
Each year, an estimated $700 billion is wasted in the US
healthcare system as a result of overuse, underuse, and
misuse of healthcare services.6 For CAD, inefficient
diagnoses of treatable disease can result in negative and
costly consequences (eg, missing significant disease,
unnecessary downstream testing) that can impact
patients (eg, unnecessary testing, delayed diagnosis
and care, worsened outcomes), providers (eg, stress,
overload), and healthcare systems (eg, reduced quality,
sustainability).10 The consequences and associated costs
partially depend on the role of a test in the diagnostic
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pathway and its convenience and availability.9 However,
studies evaluating healthcare resource utilization
(HCRU) incident to the choice of a test applied or the
factors that impact the quality and timely care of these
patients are lacking. Therefore, the purpose of this study
was to gain an understanding of HCRU and interventions associated with non-invasive testing for CAD in
either an outpatient or emergency department setting;
the current report is focused on observations in the
outpatient setting only.
METHODS
Study Design
This study was a non-interventional, retrospective,
secondary database cohort analysis of IBM MarketScan
commercial and Medicare claims data (Figure 1). The
MarketScan Commercial Database is largely an
employer-based administrative database that contains
the health insurance claims from inpatient, outpatient,
and outpatient prescription drug encounters for employees and their dependents since 1995. Coverage for
beneficiaries fall under a variety of fee-for-service and
managed care health plans, including Exclusive Provider
Organizations (EPOs), Preferred Provider Organizations
(PPOs), Point of Service Plans (POS), indemnity plans,
and Health Maintenance Organizations (HMOs). Similarly, the MarketScan Medicare Supplemental Database
contains the healthcare insurance claims (both medical
and pharmacy) for approximately 13.8 million retirees
with Medicare supplemental insurance paid for by
employers since 1995 and through 2016. Both the
Medicare-covered portion of payment and the employerpaid portion are included in this database. Both the
MarketScan Commercial and Medicare Databases

Fig. 1. Study schematic diagram. CAD coronary artery disease; HCRU healthcare resource use.
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provide detailed cost, use, and outcomes data for
healthcare services performed in both inpatient and
outpatient settings. Medical claims are linked to outpatient prescription drug claims and person-level
enrollment data through unique enrollee identifiers.
The primary study objectives were to (1) describe
the clinical and demographic characteristics of the
patient population presenting with symptoms suspicious
for CAD who received non-invasive cardiac testing in
the OP setting and (2) characterize the HCRU of the
patient population in the 45 days prior to undergoing
testing. The secondary objectives were to (1) assess
factors associated with the time from presentation of
symptoms suspicious for CAD to non-invasive diagnostic testing and (2) describe treatment patterns, cardiacrelated clinical outcomes and interventions, and HCRU
in patients diagnosed with CAD post-testing in the 90
days following CAD diagnosis.
Patients who received non-invasive CAD diagnostic
testing between March 1, 2014 and December 31, 2017
in an OP setting were identified (Figure 1). The time
frame for identifying the index visit was up to 45 days
prior to and including the testing date or the first
healthcare encounter that included a claimed precipitating reason for testing. Post-assessment interventions
were evaluated for up to 90 days after the test date in
patients who were diagnosed with CAD based on the
index diagnostic testing.
Selection of the Study Population
Included patients were aged C18 years who underwent non-invasive cardiac diagnostic testing (ETT, SE,
SPECT, CTA, CAC, stress MRI, and PET) on or after
March 1, 2014 in an OP setting (eg, physician office, OP
lab) with C18 months of continuous enrollment in the
health plan prior to testing. Patients were excluded if
they had record of the following prior to testing: a noninvasive cardiac diagnostic test; a diagnosis or claim for
revascularization, heart transplant, or heart valve surgery; or myocardial infarction (MI) or congestive heart
failure (CHF) more than 45 days before testing. Patients
who had a preoperative examination, exercise prescription, or cardiac rehabilitation in the 45 days prior to the
testing date were also excluded. Of note, patients with
MI, CAD, or CHF were allowed in the study if their first
diagnoses for any of these conditions occurred in the 45
days prior to testing since these diagnoses are indications for testing.
Analysis
All analyses were stratified by testing modality.
Time to testing was modeled using a zero-inflated

negative binomial regression model that included baseline covariates (age, gender, setting, precipitating reason
for index visit, and medication history) and testing
modality as predictors of time to testing; relative to the
reference group (patients who underwent SE), a RR
\1.0 indicated a shorter time from index visit to testing.
Variables included in the adjusted model were based on
a review of univariate effects and clinical input. To
understand associations between baseline variables and
the rate of repeat diagnostic testing and revascularization, Andersen-Gill models that included baseline
covariates and testing modality as predictors were
constructed.
RESULTS
All Screened Patients
Baseline sociodemographic and clinical
characteristics The study population included
303,052 patients; the median age was 56 years, ranging
from 52 to 59 years across testing modalities, and gender
proportions differed by testing modality (Table 1; baseline data for patients with CAD post-testing are shown in
Table S1). Chest pain was the primary precipitating
reason for the index visit (54.8%), followed by shortness
of breath (23.7%); an MI, CAD, or CHF (3.8%)
diagnosis; and other (46.8%); 3.0% of patients had no
apparent reason for testing in the last 45 days. Dyslipidemia and hypertension were the most common
comorbidities (Table 1), and SPECT was the dominant
testing modality (40.3%).
HCRU within 45 days prior to and including testing date HCRU differed by testing modality
in the 45 days prior to testing. Fewer cardiac-related OP
visits in patients undergoing CAC (mean of 3.5 for CAC
vs 3.8 for ETT and 4.0-4.8 for the other modalities) and
fewer unique OP medications in patients undergoing
CAC or ETT (mean of 2.0 for each vs 2.3-3.6 for the
other modalities; Table 2). Initiation of new cardiacrelated medications during this time was uncommon,
with the highest rate (\5%) being for antihypertensive/
antianginal medications. The most common pattern of
patient encounters with healthcare providers within 45
days prior to testing was the patient initially presenting
in an outpatient ‘‘other’’ (eg, family medicine, internal
medicine, or obstetrician-gynecology practice) setting
followed by an encounter in an outpatient cardiology/
outpatient ‘‘other’’ setting for testing. A few (10%)
patients who underwent CTA initially presented in an
OP cardiology setting, followed by testing in an OP
‘‘other’’ setting.
Factors associated with time to testing Median time to testing was [10 days across all
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Table 1. Baseline patient characteristics

Stress
MRI

ETT

SE

SPECT

CTA

CAC

PET

91,859
44,768
(48.7)
52
(44,
59)

77,708
42,619
(54.8)
55
(47,
62)

122,233
64,560
(52.8)
59
(52, 64)

5,337
2,641
(49.5)
54
(45,
61)

3,650
1,842
(50.5)
57
(50,
62)

1,902
1,113
(58.5)
59
(52,
65)

363
193
(53.2)
52
(40, 59)

303,052
157,736
(52.0)
56
(48, 62)

3,044
(3.3)
Diabetes without complications 13,569
(14.8)
Mild CKD
837
(0.9)
Moderate or severe CKD
1,215
(1.3)
Dyslipidemia
52,180
(56.8)
Gastroesophageal reflux disease 27,739
(30.2)
Hypertension
46,783
(50.9)
Cardiac rhythm disorders
25,947
(28.2)
Medication history, n (%)
Cholesterol-lowering
28,841
medications
(31.4)
Antihypertensive/antianginal
23,860
medications
(26.0)
Antiplatelet therapy
634
(0.7)
Antihypertensive medications
33,266
(36.2)
Medications to treat diabetes
9,711
(10.6)
Antianginal medications
2,179
(2.4)

3,424
(4.4)
13,339
(17.2)
885
(1.1)
1,533
(2.0)
47,584
(61.2)
24,692
(31.8)
42,550
(54.8)
22,888
(29.5)

11,095
(9.1)
35,339
(28.9)
2,262
(1.9)
4,521
(3.7)
89,686
(73.4)
46,495
(38.0)
89,179
(73.0)
38,985
(31.9)

215
(4.0)
1,035
(19.4)
60
(1.1)
59
(1.1)
3,568
(66.9)
1,883
(35.3)
3,144
(58.9)
1,813
(34.0)

107
(2.9)
525
(14.4)
41
(1.1)
55
(1.5)
2,729
(74.8)
1,035
(28.4)
1,847
(50.6)
591
(16.2)

252
(13.2)
713
(37.5)
60
(3.2)
113
(5.9)
1,442
(75.8)
763
(40.1)
1,530
(80.4)
711
(37.4)

19
(5.2)
66
(18.2)
3
(0.8)
10
(2.8)
184
(50.7)
117
(32.2)
193
(53.2)
186
(51.2)

18,156
(6.0)
64,586
(21.3)
4,148
(1.4)
7,506
(2.5)
197,373
(65.1)
102,724
(33.9)
185,226
(61.1)
91,121
(30.1)

27,380
(35.2)
23,043
(29.7)
700
(0.9)
31,318
(40.3)
9,695
(12.5)
2,122
(2.7)

57,101
(46.7)
50,302
(41.2)
2,648
(2.2)
66,656
(54.5)
25,430
(20.8)
6,472
(5.3)

2,075
(38.9)
2,670
(50.0)
68
(1.3)
2,150
(40.3)
670
(12.6)
315
(5.9)

1,412
(38.7)
852
(23.3)
20
(0.5)
1,262
(34.6)
362
(9.9)
44
(1.2)

940
(49.4)
976
(51.3)
53
(2.8)
1,215
(63.9)
529
(27.8)
102
(5.4)

122
(33.6)
162
(44.6)
3
(0.8)
165
(45.5)
56
(15.4)
11
(3.0)

117,871
(38.9)
101,865
(33.6)
4,126
(1.4)
136,032
(44.9)
46,453
(15.3)
11,245
(3.7)

N
Female, n (%)
Age, median (Q1, Q3)

Comorbidities, n (%)
Diabetes with complications

Total

CAC coronary artery calcium; CKD chronic kidney disease; CTA computed tomography angiography; ETT exercise treadmill
testing; MRI magnetic resonance imaging; PET positron emission tomography; SE stress echocardiogram; SPECT single-photon
emission computerized tomography

testing groups; median (Q1-Q3) times to testing were 11
days (3-24) for ETT, 12 days for SE (3-24) and CAC (028), 13 days (4-25) for SPECT, 17 days (7-30) for PET,
21 days (8-34) for CTA, and 25 days (7-36) for stress
MRI (Table 3). Chest pain (relative risk [RR] = 0.73)
and shortness of breath (RR = 0.90) were associated
with a shorter time to testing; presence (vs absence) of

CHF diagnosis in the 45 days prior to testing was
typically associated with a longer time to testing (RR =
1.1), while the presence (vs absence) of a MI diagnosis
in the 45 days prior to testing was associated with
shorter times to testing (RR = 0.91). With regards to
testing modality, patients undergoing ETT (RR = 0.98)
or SPECT (RR = 0.989) experienced a shorter time to
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Table 2. HCRU within 45 days prior to and including testing date

Testing modality
ETT (N = 91,859)
SE (N = 77,708)
SPECT (N = 122,233)
CTA (N = 5,337)
CAC (N = 3,650)
PET (N = 1,902)
Stress MRI (N = 363)
Total (N = 303,052)

OP encounters,
mean (SD)
3.8
4.0
4.4
4.7
3.5
4.8
4.8
4.1

Cardiac-related OP
encountersa, mean (SD)

(2.4)
(2.5)
(2.8)
(2.9)
(2.4)
(3.0)
(3.2)
(2.6)

2.2
2.2
2.4
2.8
1.0
2.6
2.5
2.3

(1.2)
(1.1)
(1.2)
(1.6)
(1.2)
(1.4)
(1.9)
(1.2)

Unique OP medicationsb,
mean (SD)
2.0
2.3
3.0
2.6
2.0
3.6
3.0
2.5

(2.4)
(2.5)
(3.0)
(2.8)
(2.4)
(3.3)
(3.2)
(2.7)

CAC coronary artery calcium; CTA computed tomography angiography; ETT exercise treadmill testing; MRI magnetic resonance
imaging; OP outpatient; PET positron emission tomography; SE stress echocardiogram; SPECT single-photon emission
computerized tomography
a
Based on a diagnosis of chest pain, shortness of breath, MI, CAD, CHF or other
b
The counts of unique OP medications are based on the generic names field in Red Book

testing compared to patients undergoing other testing
modalities (RR [1, using SE as the reference testing
modality). Furthermore, a record of a cardiologist visit
prior to or including testing date increased time to
testing.
CAD Patients With 90-Day Follow-up
Rates of repeat diagnostic testing, cardiac
catheterization, and revascularization £90
days post-CAD diagnostic testing among patients diagnosed with CAD After initial testing,
7.3% (n = 22,083) of patients (range, 4.2% [ETT
patients]—20.1% [CTA patients]) were diagnosed with
CAD, the majority (63.3%) of which were males
(Table 4). Overall, 19.4% had repeat diagnostic testing
in 90 days after initial testing, 65.6% of patients
diagnosed with CAD underwent cardiac catheterization,
and 26.0% underwent a coronary revascularization
procedure. Among patients who received repeat diagnostic testing within 90 days post-index (n = 4,200), the
testing modalities most frequently associated with repeat
testing were CAC (90-day cumulative incidence, 51.6%)
and ETT (36.7%), while patients who underwent PET,
SPECT, or CTA were less likely to undergo repeat
testing (Table 4 and Figure 2). Consistent with the
results of the 90-day cumulative incidence, patients who
underwent CAC (HR = 2.866) or ETT (HR = 2.121)
testing had significantly higher rates of repeat diagnostic
testing, while patients who underwent PET (HR=0.587),
SPECT (HR = 0.824), or CTA (HR = 0.817) had
significantly lower rates of repeat testing using SE as the
reference group. Revascularization rates were similar in

patients who underwent ETT, SE, or SPECT, while
revascularization rates were lower for CTA (HR =
0.727) and CAC (HR = 0.370) (Table 4).
Per the multivariate model, other baseline characteristics apart from testing modalities were also found to
be associated with rates of repeated diagnostic testing
and revascularization. Using 40-59 years as the reference age group, the 80? years age group had a lower
rate of repeat diagnostic testing (HR = 0.753) and
catheterization procedures (HR = 0.919); revascularization rates were higher in patients 60? years (HR = 1.241
for 60-79 years, HR = 1.331 for 80? years) and lower in
patients \40 years (HR = 0.525), who also had a lower
rate of catheterization in (HR = 0.744).This finding is
expected given lower likelihood of CAD in patients \40
years ago. Females had a higher rate of repeat diagnostic
testing (HR = 1.065) and lower rates of revascularization
(HR = 0.555) and catheterization (HR = 0.913) than
males. These constellations of findings are explained by
the challenges of non-invasive testing in women, leading
to more repetitive testing along with higher likelihood of
nonobstructive or microvascular disease in women
presenting with chest pain.11
For co-morbidities and medication history, the
reference group was those without that condition or
medication history. Patients who had history of being on
antianginal medications had lower rates of repeat
diagnostic testing (HR=0.824) and high rates of revascularization (HR = 1.333) and catheterization (HR =
1.117). Catheterization rates were lower in patients with
chronic kidney disease (HR = 0.923) or dyslipidemia
(HR = 0.973), but higher in patients with diabetes with
complications (HR = 1.084) or hypertension (HR =
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Table 3. Time to testing according to testing modality, precipitating reason for index visit, and
comorbidities

Testing modality
ETT
SE
SPECT
CTA
CAC
PET
MRI
Any cardiologist visit pre-testing
Precipitating reason for index visit
Chest Pain
Shortness of breath
MI, CAD, or CHF
Comorbidities
Myocardial infarction
Congestive heart failure

Median
(Q1-Q3)

Crude RR

Adjusted
RR

11
12
13
21
12
17
25
12

(3-24)
(3-24)
(4-25)
(8-34)
(0-28)
(7-30)
(7-36)
(3-25)

0.992
Ref.
0.994
1.345a
1.203a
1.18a
1.498a
0.999

(0.983-1.000)
(Ref.-Ref.)
(0.987-1.002)
(1.315-1.376)
(1.167-1.240)
(1.137-1.225)
(1.374-1.632)
(0.992-1.005)

0.98a
Ref.
0.989a
1.335a
1.056a
1.144a
1.361a
0.992a

(0.976-0.992)
(Ref.-Ref.)
(0.982-0.997)
(1.306-1.366)
(1.025-1.087)
(1.104-1.186)
(1.252-1.479)
(0.986-0.998)

10 (3-21)
11 (3-23)
14 (4-28)

0.732a
0.953a
1.135a

(0.728-0.737)
(0.946-0.960)
(1.122-1.148)

0.73a
0.902a
1.043a

(0.725-0.734)
(0.895-0.908)
(1.030-1.057)

15 (5-28)
21 (9-34)

1.049a
1.275a

(1.003-1.098)
(1.243-1.308)

0.912a
1.103a

(0.871-0.954)
(1.074-1.134)

(95%CI)

(95% CI)

CAC coronary artery calcium; CAD coronary artery disease; CHF congestive heart failure; CI confidence interval; CTA computed
tomography angiography; ETT exercise treadmill test; MI myocardial infarction; MRI magnetic resonance imaging; PET positron
emission tomography; RR relative risk; SE stress echocardiogram; SPECT single-photon emission computerized tomography
a
Significant adjusted HR

1.055). Additionally, patients who had chest pain (HR =
1.50) and shortness of breath (HR = 1.116) as precipitating reason for index visit and those with comorbidities such as diabetes (HR = 1.311), hypertension
(HR = 1.09) or dyslipidemia (HR = 1.088) had higher
rates of revascularization. Furthermore, increases in the
number of prescriptions were observed for some medication classes and HCRU differed by testing modality
(Table 5).
HCRU £90 days post-CAD diagnostic testing
date
among
patients
diagnosed
with CAD Overall, the median number of OP visits
were the same (median = 6) across all testing modalities,
with slightly fewer median visits seen for CAC (median
= 5); the median number of cardiac OP visits was 3 for
all modalities except for SPECT and MRI (median = 4,
both). For both general and cardiac-related inpatient and
ED visits, the median number of days did not differ
across all modalities (median = 0). For those patients
hospitalized during this 90-day time period for any
reason, the median length of stay was 6 days for all
modalities except for CTA and CAC (median = 5).

DISCUSSION
Understanding the value of and optimizing systemwide diagnostic and treatment processes (eg, reducing
time from the onset of symptoms to appropriate diagnostic testing, ensuring patients receive appropriate
follow-up), present opportunities to improve outcomes
and ensure efficient use of healthcare resources. Accordingly, the results of this study suggest that (1) patient
characteristics and symptoms drive diagnostic testing
decisions; (2) a minority of the study population tested
were diagnosed with CAD, potentially highlighting
challenges in current diagnostic testing strategies; and
(3) HCRU of medications and revascularization based
on test results reflect variations in practice. SPECT
appears to be the most common modality used for
diagnostic testing in CAD, although revascularization
rates did not differ among diagnostic modalities. Time to
testing differed by test and clinical factors after multivariate adjustment. For example, a longer time to testing
for SPECT relative to SE was anticipated based on the
known preauthorization in real-world practice; however,
time to testing was in fact shorter with a small but
potentially meaningful difference. One potential reason
for this finding is that SPECT was used in higher-risk

36.7
17.7
14.1
14.1
51.6
10.0
14.4

4.2

4.5

10.6

20.1

13.3

11.8

7.7

0.756,
0.898
0.690,
0.968
2.538,
3.236
0.392,
0.880
0.360,
2.466

0.824a

0.942

0.587a

2.866a

0.817a

Ref.

1.946,
2.311
Ref., Ref.

2.121a

95%
CI

14.8

19.9

6.6

16.5

27.3

26.4

26.5

0.636

0.817

0.370a

0.727a

1.017

Ref.

1.004

90-Day
cumulative
incidence Adjusted
(%)
HR
95%
CI

0.953,
1.084
0.624,
0.846
0.253,
0.541
0.618,
1.082
0.271,
1.495

0.929,
1.086
Ref., Ref.

Revascularization

57.8

56.7

18.9

40.7

70.7

66.5

61.0

0.941

0.925

0.321a

0.716a

1.074a

Ref.

0.906a

90-Day
cumulative
incidence Adjusted
(%)
HR

1.048,
1.101
0.663,
0.773
0.267,
0.388
0.829,
1.032
0.683,
1.297

0.877,
0.936
Ref., Ref.

95%
CI

Cardiac catheterization

a
Significant adjusted HR; adjusted HRs were considered significant if the CI did not include 1
CAC coronary artery calcium; CAD coronary artery disease; CI confidence interval; CTA computed tomography angiography; ETT exercise treadmill test; HR hazard ratio; MRI
magnetic resonance imaging; n/a not available; OP outpatient; PET positron emission tomography; SE stress echocardiogram; SPECT single-photon emission computerized
tomography

ETT (N =
3,836)
SE (N =
3,532)
SPECT (N =
12,904)
CTA (N =
1,075)
CAC (N =
484)
PET (N =
224)
Stress MRI
(N = 28)

Testing
modality

Diagnosis of
90-Day
CAD after cumulative
testing (%
incidence Adjusted
of patients)
(%)
HR

Repeat diagnostic testing

Table 4. CAD diagnoses and procedures/interventions up to 90 days post-CAD diagnostic testing among patients diagnosed with CAD
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Fig. 2. Cumulative incidence function of (A) Repeated diagnostic testing, (B) Revascularization,
and (C) cardiac catheterization in the outpatient setting. CAC coronary artery calcium; CTA
computed tomography angiography; ETT exercise treadmill test; MRI magnetic resonance imaging;
PET positron emission tomography; SE stress echocardiogram; SPECT single-photon emission
computerized tomography.
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Fig. 2. continued.

patients in our study, where it would be considered
appropriate and thus not require a lengthy preauthorization process.
One noteworthy observation pertains to the use of
CAC, which led to more retesting and less revascularization relative to the other testing modalities; this is
supported by results from previously conducted studies
in asymptomatic populations.12 Calcium score is a
reflection of overall burden of atherosclerosis, and
although higher scores may indicate a higher likelihood
of obstructive CAD, patients with markedly elevated
calcium scores may not necessarily have obstructive
disease causing ischemia.13,14 Accordingly, this test is
considered ‘‘rarely appropriate’’ in symptomatic
patients according to diagnostic guidelines as detection
of non-calcified obstructive disease may be missed in
some cases, particularly in younger patients.15 Clinicians use a low calcium score (\100) to avoid further
testing and higher calcium scores [400 to further
evaluate for ischemia. Although details of calcium score
burden are not available in the dataset for our study, the
trend of increased downstream testing reflects the
downstream effects of CAC when abnormal. ETT
followed the same trend as CAC with respect to repeat
diagnostic testing likely due to lower overall sensitivity

and specificity, thus prompting clinicians to order
further testing to evaluate for CAD depending on
clinical suspicion based on test results. Overall, there
was substantial variability between tests with respect to
medication change, repeat diagnostic testing, revascularization, and cardiac catheterization rates. Our study
suggests that some noninvasive CAD tests, such as ETT
and CAC, may lead to further downstream diagnostic
evaluations, whereas SPECT, the most commonly used
testing modality observed in this study, serve to more
efficiently triage patients for invasive testing/revascularization; these findings confirm those of other studies
that indicated the incremental benefit of SPECT as a
diagnostic strategy in higher risk patients and as a gate
keeper to avoid additional downstream testing when
SPECT is normal, given its high negative predictive
value.16
Although the SPECT group had higher catheterization rates than with SE, revascularizations were no
different between the 2 groups. Perfusion-based diagnostic tests in general have a higher sensitivity for CAD
relative to wall motion-based techniques like SE, but can
be abnormal in a multitude of conditions apart from
obstructive CAD (leading to lower specificity when
compared to invasive angiography). Clinically and
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2.6 (2.0)
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7.2 (6.0)
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8.8 (6.6)

8.3 (6.5)

Cardiacrelated OP
encountersa,
mean (SD)

5.7 (4.4)

5.8 (4.2)

6.6 (4.7)
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6.1 (4.6)
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12.0

18.9

18.6
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6.1

3.6

3.7

4.2

3.7

5.9

7.2

7.3

Unique OP
Antihypermedicationsb, Cholesterol- tensive or
Antiang- Antihypermean (SD)
lowering
antianginalc Antiplatelet
inal
tensive

CAC coronary artery calcium; CTA computed tomography angiography; ETT exercise treadmill testing; HCRU healthcare resource use; MRI magnetic resonance imaging; OP
outpatient; PET positron emission tomography; SE stress echocardiogram; SPECT single-photon emission computerized tomography
a
Based on a diagnosis of chest pain, shortness of breath, MI, CAD, CHF or other
b
The counts of unique OP medications are based on the generic names field in Red Book
c
Antihypertensive/antianginal agents include calcium channel blockers, beta blockers, and combination products

ETT (N =
3,836)
SE (N =
3,532)
SPECT (N =
12,904)
CTA (N =
1,075)
CAC (N =
484)
PET (N =
224)
Stress MRI
(N = 28)
Total (N =
22,083)

OP
Testing
encounters,
modality mean (SD)

Med Management Change
(% Increased Post-Testing)

Table 5. HCRU up to 90 days post-CAD diagnostic testing among patients diagnosed with CAD
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prognostically relevant perfusion abnormalities can be
detected even in the absence of CAD (such as diffuse
non-obstructive atherosclerosis or microvascular disease
secondary to comorbidities such as diabetes and hypertension).17,18 Hence, it is likely that there is a higher
referral bias related to abnormal SPECT for catheterizations, but not necessarily leading to revascularizations.
Our findings also reflect on some management
trends following CAD diagnosis, as not all patients are
started on cardiac medications or referred for cardiac
catheterization when diagnostic studies are abnormal.
The reasons for this are multifactorial and cannot be
fully gleaned from this study; however, similar trends
have been noted in prior publications. For example, the
relatively low frequency of referrals for patients with
abnormal functional studies has been previously
reported according to the SPARC multicenter registry
study, which also evaluated multiple noninvasive diagnostic modalities, including SPECT, PET, and CTA.19
In this study, \50% of patients with significant perfusion abnormalities were referred for cardiac
catheterization; furthermore, use of medications following an abnormal scan were suboptimal as \50% of
patients were prescribed a medication change. We found
that the use of some CAD-related medication classes
increased substantially in the 90-day time period following testing, indicating that an objective CAD
diagnosis (compared to suspicion) prompted the initiation of treatment. Furthermore, revascularizations,
which have been shown to improve quality of life and
prevent cardiovascular death,20 were performed in one
quarter of the patients in our study. Another point of
interest was the type of healthcare encounters prior to
testing and following a CAD diagnosis; few patients had
a cardiology OP visit before the testing visit, and the
number of cardiology OP visits (median visits = 3)
during the 90 days following a CAD diagnosis was
lower than the median number of ‘‘other’’ OP visits
(median visits = 6). However, further research into
patient access to a cardiologist before and after a CAD
diagnosis is needed to determine whether these differences impact outcomes. Lastly, considering only *7%
of patients who underwent non-invasive testing in this
study received a CAD diagnosis, avoidance of unnecessary testing and/or testing low-risk populations is
another factor that should be addressed in improving
CAD diagnostic testing pathway efficiency.
A strength of this study is that it was informed by
data from the IBM MarketScanÒ database, which is a
large and generalizable US-based claims dataset, making it well-suited for addressing the study objectives.
However, there are several limitations that should also

be noted. As with any retrospective database study, the
findings may be limited by the availability of data or
duration of follow-up of patients within the databases.
Additionally, the study was a non-interventional study
and was not designed to influence diagnostic procedures.
We relied on symptoms (eg, chest pain, dyspnea, etc)
presented at the visit as a trigger to order tests. However,
the reliability of this approach in calculating the time
period between ordering a test and performance is based
solely on reasonable clinical expectations. Additionally,
since administrative claims data are collected for billing
rather than research purposes, typical limitations apply.
Specifically, for the IBM MarketScanÒ Commercial and
Medicare Supplemental claims databases, Medicare
patients are underrepresented, and no Medicaid beneficiaries are captured. Lastly, while criteria were applied
to identify patients only suspected of CAD, it is possible
that patients who received a historical CAD diagnosis
may have been included in the study. Additionally, the
classification of patient records and interventions over a
defined time period can be challenging; in our study, the
45-day period prior to testing was informed by clinical
expertise; however, it is possible that the work-up to
CAD testing began earlier than 45 days prior.
In conclusion, according to this large real-world
data sample of patients who received a CAD diagnosis
per non-invasive testing modalities in an OP setting,
there are opportunities to improve upon and optimize
healthcare system-wide HCRU and value-based treatment decisions for patients at risk for CAD.
NEW KNOWLEDGE GAINED
Large studies of real-world trends in delivery of
patient care towards CAD diagnoses are sparse, and this
study provides insights into testing modalities adopted
as part of diagnosing CAD. It includes evaluation of all
modalities of non-invasive testing used for assessment
of suspected CAD, time to diagnosis, and subsequent
actionable care delivered (including additional testing,
invasive evaluation, and medication changes by testing
modality).
Our study identifies key trends where more research
is needed, such as reevaluation of identifying the right
patient population for diagnostic testing as a whole for
suspected CAD, the continued role of SPECT as an
important modality adopted for CAD (leading to less
retesting), and reaffirming medical management trends
and use of SPECT as an effective gatekeeper. These
trends may help define how clinicians can improve
patient care and adopt the appropriate testing and
management strategies for stable CAD.
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